{"id":36117,"date":"2021-07-27T09:00:00","date_gmt":"2021-07-27T07:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/"},"modified":"2021-07-27T09:00:00","modified_gmt":"2021-07-27T07:00:00","slug":"ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/","title":{"rendered":"Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose"},"content":{"rendered":"<ul>\n<li style=\"list-style-type:none;margin-bottom:3px\">\n<ul>\n<li style=\"margin-bottom:3px\">Le m\u00e9dicament exp\u00e9rimental BKX-001 est une petite mol\u00e9cule administr\u00e9e par voie orale qui active la prot\u00e9ine BAX, d\u00e9velopp\u00e9e comme<br \/>traitement potentiel de la leuc\u00e9mie, des lymphomes et des tumeurs solides1<\/li>\n<li style=\"margin-bottom:3px\">Ipsen obtient une licence exclusive pour la recherche, le d\u00e9veloppement, la fabrication et la commercialisation d\u2019un nouveau traitement ciblant la prot\u00e9ine-X associ\u00e9e \u00e0 BCL-2 (BAX), un effecteur de l\u2019apoptose<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">Ipsen et BAKX Therapeutics Inc. poursuivront ensemble les activit\u00e9s de recherche et de d\u00e9veloppement du m\u00e9dicament et partageront les b\u00e9n\u00e9fices de la commercialisation<\/li>\n<\/ul>\n<p>  <b>Paris (France), le 27\u00a0juillet 2021<\/b>\u00a0\u2013 Ipsen (Euronext: IPN\u00a0; ADR\u00a0: IPSEY) et BAKX Therapeutics Inc. ont sign\u00e9 un accord exclusif de collaboration mondiale pour la recherche, le d\u00e9veloppement, la fabrication et la commercialisation du BKX-001 dans le traitement potentiel de la leuc\u00e9mie, des lymphomes et des tumeurs solides.<br \/>L\u2019apoptose est un processus naturel entra\u00eenant la mort des cellules. Lorsqu\u2019elle est d\u00e9r\u00e9gul\u00e9e, l\u2019apoptose provoque une division cellulaire incontr\u00f4l\u00e9e et excessive conduisant \u00e0 la formation d\u2019une tumeur.2\u00a0La voie de signalisation cellulaire conduisant \u00e0 l\u2019apoptose s\u2019est av\u00e9r\u00e9e \u00eatre une cible efficace pour le traitement du cancer avec le d\u00e9veloppement et l\u2019approbation d\u2019inhibiteurs de BCL-2 pour traiter certaines h\u00e9mopathies malignes.3\u00a0BAX est une nouvelle cible dans cette voie qui intervient en aval de toutes les prot\u00e9ines anti-apoptotiques comme BCL-2, BCL-XL, MCL-1 etc.4\u00a0L\u2019activation directe de la prot\u00e9ine BAX pr\u00e9sente plusieurs b\u00e9n\u00e9fices possibles dans le traitement contre le cancer potentiellement dans diff\u00e9rents types de tumeurs mais aussi en tenant compte de la r\u00e9sistance rencontr\u00e9e lorsque seules les prot\u00e9ines anti-apoptotiques de la famille BCL-2 sont cibl\u00e9es. Il a \u00e9t\u00e9 d\u00e9montr\u00e9 que l\u2019activation de BAX par de petites mol\u00e9cules agonistes favorise l\u2019apoptose dans les lign\u00e9es leuc\u00e9miques et les \u00e9chantillons humains des cellules leuc\u00e9miques, tout en \u00e9pargnant les cellules saines in vitro, permet de supprimer les x\u00e9nogreffes de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb humaine, et augmente la survie de l\u2019animal h\u00f4te sans toxicit\u00e9 in vivo.5<br \/>Le Docteur Howard Mayer, Vice-Pr\u00e9sident ex\u00e9cutif, Directeur de la Recherche et du D\u00e9veloppement, a d\u00e9clar\u00e9 : \u00ab<em>\u00a0Dans le cadre de notre strat\u00e9gie, nous continuons \u00e0 renforcer notre portefeuille de produits en R&amp;D et \u00e0 saisir des opportunit\u00e9s d\u2019innovation externe passionnantes.<\/em>\u00a0<em>Nous sommes ravis de nous associer \u00e0 l\u2019\u00e9quipe d\u2019experts scientifiques de BAKX Therapeutics Inc. pour faire avancer le d\u00e9veloppement pr\u00e9clinique du BKX-001 jusqu\u2019au stade de candidat-m\u00e9dicament et l\u2019\u00e9valuer dans le traitement potentiel des h\u00e9mopathies malignes et des tumeurs solides.<\/em>\u00a0<em>Surtout, cette collaboration refl\u00e8te des valeurs communes entre nos deux organisations qui garantissent que nous formerons une excellente \u00e9quipe pour d\u00e9velopper cette innovation, au b\u00e9n\u00e9fice des personnes atteintes de ces formes de cancer et de leurs \u00e9quipes de soins.<\/em>\u00a0\u00bb<br \/>Sree Kant, fondateur et CEO de BAKX Therapeutics Inc. a d\u00e9clar\u00e9 : \u00ab\u00a0<em>Nous nous r\u00e9jouissons de nous associer \u00e0 Ipsen pour acc\u00e9l\u00e9rer le programme de R&amp;D du BKX-001.<\/em>\u00a0<em>Ce programme est le r\u00e9sultat de travaux pionniers sur la prot\u00e9ine BAX, men\u00e9s par nos co-fondateurs scientifiques Loren D Walensky et Evripidis Gavathiotis.<\/em>\u00a0<em>Ce partenariat associe l\u2019expertise d\u2019Ipsen en d\u00e9veloppement clinique et commercial \u00e0 nos connaissances pouss\u00e9es sur la prot\u00e9ine BAX et \u00e0 notre plateforme informatique unique qui nous permet de concevoir des m\u00e9dicaments d\u2019apr\u00e8s les interactions prot\u00e9ine-prot\u00e9ine.<\/em>\u00a0<em>Notre collaboration se caract\u00e9rise par une tr\u00e8s forte compl\u00e9mentarit\u00e9 qui nous permettra de r\u00e9aliser ensemble d\u2019importantes avanc\u00e9es dans le traitement du cancer pour les patients, et ce plus rapidement.\u00a0<\/em>\u00bb  A la signature de l\u2019accord, Ipsen verserait \u00e0 BAKX Therapeutics Inc. un paiement initial de 14,5\u00a0millions de dollars, suivi de paiements \u00e0 l\u2019atteinte de certaines \u00e9tapes pouvant aller jusqu\u2019\u00e0 837,5\u00a0millions de dollars. Les deux entreprises partageront \u00e0 parts \u00e9gales les b\u00e9n\u00e9fices et les co\u00fbts de la commercialisation et du d\u00e9veloppement. <\/li>\n<\/ul>\n<ol>\n<li style=\"margin-bottom:3px\">BAKX Therapeutics. The apoptosis company. Pipeline.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtCwbt32kE6tAtLcUn2qRmcVsDHLcuF0FQXHCUgv5f2L6vduv4w7TU_GdnaeFPqQy-zTmGLkGUfSAkW0KyN3SekPH4K-nUP9iZYVbhDm_RVM8fS4Y9pB7i9SP7H7OnyW\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/bakxtx.com\/pipeline\/<\/b><\/a>\u00a0(last accessed July 2021).<\/li>\n<li style=\"margin-bottom:3px\">National Human Genome Research Institute.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtCwbt32kE6tAtLcUn2qRv4JkAb4wzmwnYJCCozXVhD4SidyLCGG7NgFYBf8Gj-c9SSyyVCV215XJeYgbXfYTPvmEwkvy8k6ByCUAH8uuuphK3_M_iJIBRvqvVv5y3VPL0RP7HfnboV8n8CSwQZ1y39PIWf1i5_pCw9ln4RpvLc=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/www.genome.gov\/genetics-glossary\/apoptosis<\/b><\/a>\u00a0(last accessed July 2021).<\/li>\n<li style=\"margin-bottom:3px\">Venclyxto SmPC. European Medicines Agency. Available here:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtCwbt32kE6tAtLcUn2qRqkoT5QUKZpAteeUQlVGX-VISSRF-vpsByQ3P-nHKYk7PJYj0Bv-l3l5FFkMg8ktnlCmRrFXobyfq14sJVLEtsogZKzCQa_kJ1BjRM7aXuLFYZiJhgHwLk0O7SxHVYYkgcfbmQ5GtLThDxy8Ny2wY08ubh17_F-mqaypRQe_8U9L\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/venclyxto<\/b><\/a><\/li>\n<li style=\"margin-bottom:3px\">A.R.D. Delbridge and A. Strasser Cell Death Differ., 22 (2015), pp. 1071-1080. Available here:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtCwbt32kE6tAtLcUn2qRgFCAMJ3dpfyE8HN0sXl8fMJNyeBU4bINOfxb8hGSBPf8g_JSOudM705ENTjjr_GKnwF8QD-G6w1p2fo96qmxSphqkqzhacUbsTeMGz920UhMkA6dHF78MUgAx3Obh192A==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/www.nature.com\/articles\/cdd201550<\/b><\/a>.<\/li>\n<li style=\"margin-bottom:3px\">D.E. Reyna, T.P. Garner, A. Lopez, F. Kopp, G.S. Choudhary, A. Sridharan, S.R. Narayanagari, K. Mitchell, B. Dong, B.A. Bartholdy et al. Cancer Cell, 32 (2017), pp. 490-505. Available here:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtCwbt32kE6tAtLcUn2qRnon2VwOZEJ163R805iK65Sy3H182NlNe5i-DmFjTvlHyZTeOGzkJshcRolMofdugW09OylCy7epxeBuh2Ik_Ja-dVMrHoBXwwE8NdGN8dd9EM_yZCxJYZwjSs1A2vYKt_iIqjNU44aMl0fSsXri5xZLPER5vNefjvkGoI3bCjUlxi_eqlZKav0_0OTrx4bPFw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/www.cell.com\/cancer-cell\/fulltext\/S1535-6108(17)30364-1<\/b><\/a><\/li>\n<\/ol>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Pi\u00e8ce jointe<\/strong>\n<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=yDd4meqRVVXyabtcZ4G59ya3u2jNXMXebWppM0JTZmfPdA4MWPSKdScab69JM7Oh7wn9fZMBBeVr6YTJuAoFbOkQI1osm3QwmfyrntErJAHblcoziCqPs7kdlZspLVoCQSi_GikruvElDfgg1lpyAgwwO8IoS46_xjIqZ1kgzs446cUbxv3HtnEKvMD5PN3nxRwgAsJP3XrpECHhhmPqvQ==\" title=\"Ipsen-Collaboration-BAKX-27-Juillet-2021\" rel=\"nofollow noopener\">Ipsen-Collaboration-BAKX-27-Juillet-2021<\/a>\n      <\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556,3560,3562],"tags":[],"class_list":["post-36117","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","category-oncology-pressrelease-fr","category-partnering-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352\"},\"headline\":\"Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose\",\"datePublished\":\"2021-07-27T07:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/\"},\"wordCount\":831,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\",\"Oncologie\",\"Partenariat\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/\",\"name\":\"Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2021-07-27T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose","og_url":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/","og_site_name":"Global","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352"},"headline":"Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose","datePublished":"2021-07-27T07:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/"},"wordCount":831,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate","Oncologie","Partenariat"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/","url":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/","name":"Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2021-07-27T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-renforce-son-portefeuille-en-oncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-bakx-therapeutics-inc-pour-le-bkx-001-une-molecule-ciblant-la-voie-de-la\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen renforce son portefeuille en Oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec BAKX Therapeutics Inc. pour le BKX-001, une mol\u00e9cule ciblant la voie de l\u2019apoptose"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36117\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}